Dose Finding Study to Treat High Phosphate Levels in the Blood.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

Also called NCT02081534

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 162 participants (enrolled count) (from the registry)
Sponsor
  • Ardelyx Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02081534
Other papers using this trial's data
  • The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019-02-01 DOI, PubMed 29617976, PMC6365767 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Poland, Slovakia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02081534. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2020-09-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose Finding Study to Treat High Phosphate Levels in the Blood.
Condition
Hyperphosphatemia
Intervention (Drug)
AZD1722
Intervention (Drug)
Placebo
Lead sponsor
Ardelyx (class: industry)

Record details

Record id
cardio:ct-nct02081534
Content hash
7095bc7a01243d07278adbbbade029b00854a9b9980edb4d6fdb5b63a2c7a238